Processes for preparing &bgr;-D-ribofuranose derivatives

Details Processes for preparing &bgr;-D-ribofuranose derivatives Processes for preparing &bgr;-D-ribofuranose derivatives

2002-12-06

2003-12-09

Barts, Samuel (Department: 1623)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S028700, C536S018700, C536S124000

Reexamination Certificate

active

06660854

ABSTRACT:

This application is based upon and claims priority from Korean Patent Application No. 10-2001-76802 filed Dec. 6, 2001, the contents of which are incorporated herein by reference.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a process for preparing &bgr;-D-ribofuranose derivatives, which are useful as an intermediate for the preparation of ribavirin with an antiviral activity.
2. Description of the Related Art
&bgr;-D-Ribofuranose derivatives are useful as an intermediate for the preparation of ribavirin. Processes for the preparation thereof are disclosed in U.S. Pat. No. 3,798,209 and
J. Med. Chem.,
1972, Vol. 15, No.11, 1150~1154. The process disclosed in U.S. Pat. No. 3,798,209 may be summarized in the following reaction scheme 1:
In the above reaction scheme 1, Bz is a benzoyl group.
However, it takes about 3 days to complete the reaction of the above process. Further, additional isolation processes are necessary because the compounds of formula (I″) are also produced as a by-product. In order to carry out the isolation processes, re-crystallization and/or column chromatography are conventionally performed, which complicates an industrial-scale mass production.
The process disclosed in
J. Med. Chem.,
1972, Vol. 15, No. 11, 1150~1154 is illustrated in the following reaction scheme 2:
In the above reaction scheme 2, Ac is an acetyl group; and R
1
is a protecting group for hydroxyl group.
The reaction, as shown in the scheme 2, is carried out at a high temperature, such as 160~165° C., which causes a degradation of compounds including reactants and products. Degraded compounds are changed into tar, which makes it difficult to isolate and purify an end product. The yield of the end product through the above process is relatively low, i.e., about 74~78%. There is needed an additional distillation equipment under a reduced pressure, in order to remove acetic acid that is generated during the reaction.
Further, N,O-bis(p-nitrophenyl) phosphate, used as a catalyst, is very expensive reagent, which is unfavorable for industrial-scale mass production of &bgr;-D-ribofuranose derivatives. Moreover, since the above process gives the compound of formula (I′″) with gray color (i.e., low purity), an additional purification process is required in order to produce a high purity of ribavirin.
SUMMARY OF THE INVENTION
The present invention provides a process for preparing &bgr;-D-ribofuranose derivatives in high purity and yield under a mild condition, so as to be favorably applied to a large-scale mass production thereof.
In one aspect of the present invention, there is provided a process for preparing a compound of formula (I), which comprises (a) reacting a compound of formula (II) with a compound of formula (III) at 80° C.~120° C., in the presence of a catalyst selected from the group consisting of methanesulfonic acid, benzenesulfonic acid and p-toluenesulfonic acid; and (b) crystallizing the resulting compound obtained in the step (a):
wherein, R
1
is a protecting group for hydroxyl group; and R
2
is a C
1
-C
4
alkyl group.
DETAILED DESCRIPTION OF THE INVENTION
In one embodiment of the present invention, a compound of formula (II) and a compound of formula (III) are reacted under a mild condition in the presence of a catalyst and a resulting compound is crystallized, in accordance with the following reaction scheme 3 described below:
In the above reaction scheme 3, R
1
is a protecting group for hydroxyl group; and R
2
is a C
1
-C
4
alkyl group.
The compounds of formula (II) and (III), which are starting materials in the process of the present invention, may be prepared by a method which is known in the art (e.g.,
J. Med. Chem.,
1972, Vol. 15, No. 11, 1150~1154).
The protecting group for hydroxyl group includes any conventional protecting groups which are acceptable for the preparation of antiviral agents, such as acetyl group, benzoyl group and etc.
The eq. ratio of the compound of formula (II): the compound of formula (III) is preferably 1:1.0~1.2. Where eq. ratio of the compound of formula (III) to the compound of formula (II) is less than 1, the compound of formula (II) may remain un-reacted. Where the compound of formula (III) is used more than 1.2 eq. to 1 eq. of the compound of formula (II), the color of the product, i.e., the compound of formula (I), may be changed (yellow). Further, un-reacted compound of formula (III), which could remain in the reaction system, may be converted to 1,2,4-triazole-3-carboxamide during a subsequent ammonolysis for the preparation of ribavirin, which then remains as one of impurities.
In reacting the compounds of formula (II) and (III), a higher temperature raises the rate of the reaction. However, considering purity and yield of the product, the reaction is preferably performed at 80° C.~120° C., more preferably 90° C.~100° C.
The catalyst is selected from the group consisting of methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid. These catalytic compounds are much cheaper than N,O-bis(p-nitrophenyl) phosphate. In addition, the catalyst allows the reaction to be carried out under a milder condition. Thus, a high reaction temperature can be avoided. Among those catalytic compounds, p-toluenesulfonic acid is preferable, in the aspect of the yield of the product.
The catalyst may be added to the reaction mixture preferably at a ratio of 0.01~0.05 eq. based on 1 eq. of the compound of formula (II), considering the yield of the product.
The reaction of the compounds of formula (II) and (III) does not require a solvent. That is, both compounds of formula (II) and (III) melt at the reaction temperature (i.e., 80° C.~120° C.) and the reaction proceeds by adding the catalyst. The reaction may be completed within preferably 3~6 hours, more preferably 4~5 hours.
In crystallizing the resulting compound, a solvent is used. The solvent for crystallization includes an alcohol, such as methanol, ethanol, butanol, isobutanol, and an aqueous solution thereof. Among them, more preferable solvent for crystallization is methanol, considering a purity of the product, a compound of formula (I).
The compound of formula (I) obtained according to the present invention can be converted to ribavirin in accordance with conventional methods disclosed in, e.g., U.S. Pat. No. 3,798,209 and
J. Med. Chem.,
1972, Vol. 15, No. 11, 1150~1154. For example, through ammonolysis and re-crystallization, high purity ribavirin of white color can be easily obtained from the compound of formula (I) without any additional purification and/or decolorization.
The present invention is further illustrated and described by the following examples, which should not be taken to limit the scope of the invention.


REFERENCES:
patent: 3798209 (1974-03-01), Witowski et al.
patent: 44080070 (1974-08-01), None
Sunagawa et al. (JP 49080070). (abstract sent).*
Zhou (Zhongguo Yaowu Hauxue Zazhi (1996), 6(2), 133-135). (abstract sent).*
J.T. Witowski et al.,Journal of Medicinal Chemistry,vol. 15, No. 11, 1972 Design, Synthesis, and Broad Spectrum Antiviral Activity of 1-&bgr;-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide and Related Nucleosides.

Affiliated with

Also associated with

Rating

Processes for preparing &bgr;-D-ribofuranose derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Processes for preparing &bgr;-D-ribofuranose derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Processes for preparing &bgr;-D-ribofuranose derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3180100